Rockland is expected to construct vectors of some of the anti-cancer drugs Herceptin, Rituxan, Zevalin and Erbitux to accelerate the development of the generic version of these antibodies.
Rockland Immunochemicals president Jim Fendrick said that Rockland’s antibody technology platform continues to be widely received by the research and biopharma community.
"We anticipate success in our antibody efforts to discover and develop both new and existing antibody targets that have application in the research, diagnostic and therapeutic markets," Fendrick said.